Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Michael Bidder who wrote (2966)	9/23/1998 11:05:00 AM
From: Bill Wexler	Read Replies (4) \| Respond to of 4634

Pump and dump. It'll eventually go to zero since the science is nothing but fraud and quackery. In the meantime, the stock can go all over the map.

To: Michael Bidder who wrote (2966)	9/23/1998 11:15:00 AM
From: Mama Bear	Read Replies (3) \| Respond to of 4634

All manner of garbage has been floating up lately. OCOM near 6 ENML 5 1/2 ALTIF ran to 10 I'm sure there are others. Barb

To: Michael Bidder who wrote (2966)	9/23/1998 11:47:00 AM
From: Spunky Beaver	Respond to of 4634

Plumber's rule in effect today; Sh*t floats!

To: Michael Bidder who wrote (2966)	9/23/1998 12:08:00 PM
From: Bob Trocchi	Respond to of 4634

Michael... Found the following article on the biotech industry and I copied a portion of it where HEPH was mentioned. This IMO is having a positive rice impact on today's stock price. The full article mentions a few biotech/analyst conferences this week and thus I would expect upward pressure all week. FYI... Although tempted to go short, I have no position in HEPH. >>One tiny California company, Hollis-Eden Pharmaceuticals (HEPH), has seen its shares triple since touching a low on Oct. 27, 1997. Hollis-Eden receives practically no coverage from the investment community. The San Diego company is working on drug combinations for the treatment of AIDS, Hepatitis and organ transplant rejections. Bill Corbett at The Shemano Group in San Francisco says the company's Inactivin interrupts cellular factors, thus inhibiting AIDS' HIV virus from replicating. "The stock is rearing its head," said Corbett on Wednesday. "But it's still really early stage." Shemano Group raised almost $20 million for the company in a private placement. Corbett said Inactivin might begin Phase 1 trials in two months.<< cbs.marketwatch.com